Moderna Inc. (MRNA)
Moderna, Inc. (MRNA) 7th Annual Evercore ISI HealthCONx Conference - (Transcript)
Moderna, Inc. (NASDAQ:MRNA ) 7th Annual Evercore ISI HealthCONx Conference Call December 4, 2024 1:20 PM ET Company Participants Lavina Talukdar - Senior Vice President and Head of Investor Relations Conference Call Participants Cory Kasimov - Evercore ISI Cory Kasimov Good afternoon, everyone. I'm Cory Kasimov, one of the senior biotech analysts here at Evercore ISI.
Moderna: Optimistic Outlook Despite The Recent Sell-Off
Moderna's stock is undervalued, so I maintain a positive outlook with a $97 price target for next year. 3Q24 results show good COVID-19 revenue, cost efficiency, and a significant cash balance, but RSV vaccine sales underperformed. The pipeline includes promising next-gen COVID-19, RSV, flu, CMV, norovirus, and oncology drugs, with substantial revenue potential by 2027.
Moderna to Present at Upcoming Conferences in December 2024
CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: 7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ET Piper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
Moderna Stock Jumps Following Bullish Sales View at Healthcare Conference
Moderna (MRNA) shares surged further Friday, a day after a senior executive made bullish comments at a healthcare conference about the vaccine maker's pipeline and cash position.
Moderna, Inc. (MRNA) Presents at Jefferies London Healthcare Conference (Transcript)
Moderna, Inc. (NASDAQ:MRNA ) Jefferies London Healthcare Conference November 21, 2024 9:00 AM ET Company Participants Lavina Talukdar - IR Conference Call Participants Michael Yee - Jefferies Michael Yee Good afternoon everyone. Thank you for joining us on the next session.
BioNTech and Moderna at vanguard of new treatment wave - but which is best?
The mRNA (messenger RNA) technology that powered the rapid development of COVID-19 vaccines is now driving a broader revolution in medicine. According to Berenberg, this innovative approach has the potential to transform the treatment of multiple ailments, particularly cancer and infectious diseases.
Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
Last week, some large European and U.S. vaccine maker stocks fell in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
Cramer's Mad Dash: Moderna gets upgrade from HSBC
CNBC's Jim Cramer reports on the latest news regarding Moderna.
Moderna, Inc. (MRNA) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)
Moderna, Inc. (NASDAQ:MRNA ) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 10:00 AM ET Company Participants Stephen Hoge - President Conference Call Participants Evan Wang - Guggenheim Securities Evan Wang [Call Starts Abruptly] Inaugural Health Innovation Conference. I'm Evan Wang, one of the senior biotech analysts at Guggenheim.
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
Shares in some of America's largest drug manufacturers tumbled yesterday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his pick for secretary of the Department of Health and Human Services (HHS).
Moderna And Other Vaccine Maker Stocks Tumble After Trump Taps RFK Jr. As HHS Head
Stocks linked to vaccine developers such as Moderna, Pfizer and Novavax tanked in the leadup to market close Thursday, tumbling after reports surfaced that President-elect Donald Trump would select vaccine skeptic Robert F. Kennedy Jr. as the head of the Department of Health and Human Services.
Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS
Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and former presidential hopeful Robert F. Kennedy Jr. as his pick to lead the U.S. Department of Health and Human Services.
